サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1736748

体外式膜酸素化装置市場：部品別、サービス別、患者タイプ別、用途別、地域別、2026～2032年

Extracorporeal Membrane Oxygenation Machine Market By Component (Pumps, Cannula), By Services (Veno-Venous, Veno-Arterial), By Patient Type (Adult, Pediatric), By Application (Respiratory, ECPR), And Region for 2026-2032

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
体外式膜酸素化装置市場：部品別、サービス別、患者タイプ別、用途別、地域別、2026～2032年
出版日: 2025年05月06日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

体外式膜酸素化装置（ECMO）市場の評価-2026～2032年

患者パラメータのリアルタイム評価と追跡を可能にする先進的センサとモニタリングシステムの進歩と活用の拡大が、体外式膜酸素化装置市場の成長を促進しています。特に新興地域におけるヘルスケア産業の成長は、ECMO市場に新たな機会を生み出しており、2024年には6億2,323万米ドルの評価額を上回り、2032年には約9億3,281万米ドルの評価額に達する見込みです。

これに加えて、技術の進歩がECMO装置の使用におけるヘルスケア専門家の実践を強化し、多様な臨床環境におけるECMO装置の利用拡大に寄与しています。この技術によって患者の生存率が向上し、ニッチ市場は2026～2032年にかけてCAGR 5.75％で成長します。

体外式膜酸素化装置市場定義/概要

体外式膜酸素化装置は、人工心肺を介した血液の外部循環を行っています。この装置は二酸化炭素を効果的に除去する一方、酸素を濃縮した血液を循環系に戻します。心臓の右側から人工心肺に血流が送られます。その後、物質は再加熱され、体内に戻されます。

ECMOは、患者の血液を外部回路に流し、そこで酸素を供給し、二酸化炭素を除去してから体内に戻します。ECMOは、重症心不全、呼吸不全（ARDSや肺炎など）、心臓手術後の合併症などの場合によく使用されます。ECMOは、新生児や小児医療への応用が進んでおり、先天性欠損症や重度の呼吸困難のある乳児の生存率を著しく向上させています。機能不全に陥った臓器の機能を一時的に代行するECMOの能力は、患者を安定させ、機能不全の根本原因に対処するための重要な窓口を医師に記載しています。

心臓と呼吸器疾患の発生率の増加は、市場拡大をどのように促進しているか？

心肺疾患の有病率の増加は重要な問題であり、ECMO装置を含む医療介入の強化の必要性を浮き彫りにしています。心不全、心筋梗塞、心停止などの心疾患は、人口の高齢化、座りがちなライフスタイル、食生活の乱れ、高血圧、肥満、糖尿病などの危険因子の有病率の増加などの要因により増加傾向にあります。これらの病態は、従来型治療では十分でないような生命を脅かす状況につながることが多いため、ECMOシステムは、基礎疾患の治療中に酸素化と循環機能を維持することによって生命維持を行う上で不可欠なものとなってきています。

急性呼吸窮迫症候群（ARDS）は、肺の小さな気嚢に液体が蓄積し、血流への酸素の効率的な移行を阻害することを特徴とします。重篤な呼吸器疾患へとエスカレートする可能性があり、効果的な呼吸補助のために外部からの支援が必要となります。心原性ショックは、心臓が身体の要求を満たすのに十分な血液を効果的に送り出すことが突然できなくなることを特徴とする重篤な病状であり、速やかに対処しなければ臓器不全に至る可能性があります。

患者数の増加により、ECMO装置の需要が高まっています。ECMO装置は心臓と肺の代用として機能し、これらの重要臓器の休息と回復を促進します。この技術は、代替治療に反応しない患者を管理する集中治療室で不可欠となっています。心肺障害の有病率の増加は、ECMO装置市場に影響を与える重要な要因です。

ECMO装置と処置に関連する費用の上昇は市場拡大の妨げになるか？

体外式膜酸素化装置は、心不全や肺不全に陥った患者の生命維持に重要な役割を果たします。核心的な問題は、ECMO装置に関連する多額の費用であり、しばしば数十万米ドルに達します。また、この治療法には、訓練を受けた灌流専門医、集中治療室（ICU）スタッフ、継続的な患者のモニタリングなど、高度に専門化された医療チームが必要であり、人件費がかさむとともに、ECMO治療を提供できる病院の数も限られています。

これは、その製造プロセスで最先端技術と革新的な材料を利用していることに起因します。全体的なコストはさらに、これらの機械に関連する維持費や運用費に影響されます。ECMO治療には、外科医、看護師、打楽器奏者からなるヘルスケア専門家チームが必要であり、これが総治療費の一因となっています。

目次

第1章 体外式膜酸素化装置の世界市場のイントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査スケジュール
  • 前提条件
  • 制限事項

第2章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • データの三角測量
  • ボトムアップアプローチ
  • トップダウンアプローチ
  • 調査の流れ
  • 産業専門家による主要な洞察
  • データソース

第3章 エグゼクティブサマリー

  • 市場概要
  • エコロジーのマッピング
  • 絶対的収益機会
  • 市場の魅力
  • 体外式膜酸素化装置の世界市場地域別分析
  • 体外式膜酸素化装置の世界市場：患者タイプ別（100万米ドル）
  • 体外式膜酸素化装置の世界市場：用途別（100万米ドル）
  • 体外式膜酸素化装置の世界市場：モダリティ別（100万米ドル）
  • 体外式膜酸素化装置の世界市場：部品別（100万米ドル）
  • 今後の市場機会
  • 世界市場内訳
  • 製品ライフライン

第4章 体外式膜酸素化装置の世界市場展望

  • 体外式膜酸素化装置の世界進化
  • 促進要因
    • 促進要因1
    • 促進要因2
  • 抑制要因
    • 抑制要因1
    • 抑制要因2
  • 機会
    • 機会1
    • 機会2
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 価格分析
  • マクロ経済分析

第5章 体外式膜酸素化装置の世界市場：部品別

  • 概要
  • ポンプ
  • カニューレ
  • 酸素供給器
  • 付属品
  • コントローラ

第6章 体外式膜酸素化装置の世界市場：サービス別

  • 概要
  • 静脈-動脈
  • 静脈-静脈
  • 動脈-静脈

第7章 体外式膜酸素化装置の世界市場：患者タイプ別

  • 概要
  • 成人
  • 小児
  • 新生児

第8章 体外式膜酸素化装置の世界市場：用途別

  • 概要
  • 呼吸器
    • 新生児
    • 小児
    • 成人
  • 心肺蘇生法
    • 新生児
    • 小児
    • 成人
  • 心臓
    • 新生児
    • 小児
    • 成人

第9章 体外式膜酸素化装置の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他の中東・アフリカ

第10章 体外式膜酸素化装置の世界市場競合情勢

  • 概要
  • 企業市場ランキング
  • 企業の地域フットプリント
  • 企業の産業フットプリント
  • ACEマトリックス

第11章 企業プロファイル

  • Medtronic
  • Fresenius Medical Care A.G. & Co. KGAA
  • Maquet Holding
  • Getinge Group
  • Microport
  • Origin Biomedical
  • Terumo Cardiovascular Systems Corporation
  • Livanova plc
  • Nipro Corporation
  • Euro sets S.R.L.

第12章 VERIFIED MARKET INTELLIGENCE

  • VERIFIED MARKET INTELLIGENCEについて
  • ダイナミックデータの可視化
目次
Product Code: 40614

Extracorporeal Membrane Oxygenation Machine Market Valuation - 2026-2032

The growing advancements and the utilization of sophisticated sensor and monitoring systems enabling the real-time assessment and tracking of patient parameters is driving the growth of the Extracorporeal Membrane Oxygenation Machine Market. The growth of the healthcare industry, particularly in developing regions, is creating new opportunities for the ECMO market, surpassing USD 623.23 Million valued in 2024 to reach a valuation of around USD 932.81 Million by 2032.

In addition to this, the advancements in technology are enhancing the practice of healthcare professionals in the use of ECMO machines, thereby contributing to an increased utilization of these machines across diverse clinical environments. This technology is consequently leading to an increase in patient survival rates, enabling the niche market grow at a CAGR of 5.75% from 2026 to 2032.

Extracorporeal Membrane Oxygenation Machine Market: Definition/ Overview

The extracorporeal membrane oxygenation machine (ECMO) involves the external circulation of blood through a heart-lung machine. The device effectively eliminates carbon dioxide while delivering oxygen-enriched blood back to the circulatory system. The right side of the heart directs blood flow to the heart-lung machine. The substance is subsequently reheated and returned to the body.

ECMO works by channeling the patient's blood through an external circuit where it is oxygenated and carbon dioxide is removed before being returned to the body. It is commonly used in cases of severe cardiac failure, respiratory failure (such as ARDS or pneumonia), or post-cardiac surgery complications. ECMO is increasingly being applied in neonatal and pediatric care, where it has significantly improved survival rates for infants with congenital defects or severe respiratory distress. Its ability to temporarily take over the function of failing organs offers physicians a critical window to stabilize patients and address underlying causes of failure.

How are the Rising Incidence of Cardiac and Respiratory Conditions Propelling the Market Expansion?

The increasing prevalence of cardiopulmonary disorders is a significant issue, highlighting the necessity for enhanced medical interventions, including ECMO machines. Cardiac diseases, such as heart failure, myocardial infarction, and cardiac arrest, are on the rise due to factors like aging populations, sedentary lifestyles, poor diets, and increasing prevalence of risk factors such as hypertension, obesity, and diabetes. As these conditions often lead to life-threatening situations where traditional treatments may not suffice, ECMO systems are becoming essential in providing life support by maintaining oxygenation and circulatory functions while underlying conditions are treated.

Acute respiratory distress syndrome (ARDS) is characterized by the accumulation of fluid in the small air sacs of the lungs, impeding the efficient transfer of oxygen into the bloodstream. There is potential for escalation to severe respiratory issues, necessitating external assistance for effective breathing support. Cardiogenic shock represents a severe medical condition characterized by the heart's abrupt inability to effectively pump sufficient blood to meet the body's demands, leading to potential organ failure if not addressed promptly.

The rising patient population is leading to an escalating demand for ECMO machines. ECMO machines serve as substitutes for the heart and lungs, facilitating a period of rest and recovery for these vital organs. This technology has become essential in the intensive care unit for managing patients who do not respond to alternative treatments. The increasing prevalence of cardiopulmonary disorders is a significant factor influencing the ECMO machine market.

How Will the Elevated Expenses Associated with ECMO Machines and Procedures Hinder the Market Expansion?

The extracorporeal membrane oxygenation machine serves as a critical life support mechanism for individuals experiencing heart or lung failure. The core issue is that the substantial costs associated with ECMO machines, often reaching hundreds of thousands, represent a significant barrier to their utilization despite their remarkable capabilities. The procedure also requires highly specialized medical teams, including trained perfusionists, intensive care unit (ICU) staff, and continuous patient monitoring, which adds to labor costs and limits the number of hospitals capable of offering ECMO treatment.

This results from the utilization of cutting-edge technology and innovative materials in its production process. The overall cost is further influenced by the maintenance and operational expenses associated with these machines. ECMO procedures necessitate specialized teams of healthcare professionals, comprising surgeons, nurses, and percussionists, which contribute to the total treatment expenses.

Category-Wise Acumens

What are the Features Bolstering the Demand of Oxygenators Segment?

The oxygenators segment represented the most dominating segment in 2023 and is projected to continue its dominance throughout the forecast period. The rise in chronic diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), alongside the growing need for heart and lung transplantation procedures, can explain this trend. The World Health Organization (WHO) reported that COPD ranked as the third leading cause of death worldwide, accounting for roughly 3.23 million fatalities. The significant increase in mortality rates associated with respiratory and cardiovascular diseases is driving the expansion of the Extracorporeal Membrane Oxygenation Machine Market.

The oxygenators segment is expected to benefit from the overall advancements in ECMO technology and its expanding use in broader clinical settings, including emergency and pediatric care. As healthcare systems adopt ECMO for more patients with severe cardiac and respiratory conditions, demand for high-performance oxygenators will likely increase. Furthermore, ongoing research into biocompatibility and longevity of oxygenators is set to improve patient outcomes and reduce the risks associated with long-term ECMO use, solidifying the market dominance of this segment.

How will the Demand for Veno-Arterial Segment Impacts the Market Growth?

The veno-arterial segment represented the fastest growing CAGR in 2023 and is projected to experience robust growth at a healthy CAGR throughout the forecast period. The increase in utilization can be linked to its effectiveness in managing cases of cardiac arrest, where it plays a crucial role in algorithm-driven life support techniques aimed at reestablishing blood circulation. The rising prevalence of chronic obstructive pulmonary disease (COPD) serves as a significant factor influencing this market segment. A research paper published by BMC Pulmonary Medicine in July 2022 indicated that around 300 million individuals are affected by COPD worldwide, with a prevalence rate of about 12.2%. This underscores a considerable demand for advanced life support technologies such as ECMO machines.

Innovations in VA-ECMO technology, such as more compact and efficient devices, and the integration of real-time monitoring systems, are likely to make it more accessible in emergency care and for long-term patient management. Moreover, expanding use in treating adult and pediatric patients with complex cardiac conditions, combined with advancements in postoperative recovery, will further drive the growth of this segment across hospitals and specialized care centers during the forecast period.

Country/Region-wise Acumens

How will the Growing Cardiac Issues Drives the Market in North America?

In 2023, the North America Extracorporeal Membrane Oxygenation Machine Market had the dominating share in terms of global revenues. North American market was predominantly represented by the U.S., which held the largest share in the global market. The nation possesses a robust healthcare infrastructure and a significant patient demographic in need of ECMO machines, attributed to the widespread occurrence of chronic illnesses and a notable rate of cardiac and respiratory failures. This has led to a higher demand for advanced life support systems like ECMO, particularly the veno-arterial (VA) type, which provides both cardiac and respiratory assistance in patients suffering from severe cardiac failure. With increasing numbers of patients requiring urgent intervention for heart-related complications, hospitals and medical centers are increasingly adopting ECMO technology as a critical tool for improving survival rates.

The U.S. has maintained its position as a global leader in the innovation of medical devices, drawing in leading manufacturers of ECMO machines. Major market players such as Medtronic, a prominent player in the medical technology sector, has achieved notable advancements in the ECMO machine market. The active participation of the U.S. in the development and approval processes for ECMO machines has led to a notable rise in adoption and expansion within this market segment.

How will the Increasing Adoption of Precision Medicine Supports the Market Growth in China?

Asia-Pacific region to grow at a robust CAGR during the forecast period. China is projected to maintain a leading role in the East Asia market for extracorporeal membrane oxygenation machines. The increasing utilization of ECMO in pediatric and neonatal care represents a significant factor influencing the industry in China. The evolving healthcare sector in the country is increasingly focused on improving clinical outcomes for infants and children suffering from life-threatening cardiorespiratory conditions.

In cases involving congenital heart defects, respiratory distress syndrome, and various severe infections in neonates, ECMO serves as a critical intervention when standard treatment options are inadequate. China is channeling investments into specialized pediatric and neonatal intensive care units across major hospitals, with ECMO machines emerging as essential equipment. The demand in China is driven by the government's dedication to enhancing health services for children, alongside the growing awareness among healthcare professionals regarding the effectiveness of ECMO in pediatric care.

Competitive Landscape

The Extracorporeal Membrane Oxygenation Machine Market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the Extracorporeal Membrane Oxygenation Machine Market include:

Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Maquet Holding, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, Abiomed.

Latest Developments

In July 2023, the ASAIO Conference showcased BreathMo, an advanced ECMO system, highlighting China's innovation in the field of medical technology. This innovative maglev technology effectively meets the specific medical requirements of patients in China, representing a significant progression in the sector.

In April 2023, Abbott obtained two new approvals from the U.S. Food and Drug Administration (FDA) for its renowned life support system, specifically the CentriMag Blood Pump. The expanded FDA indication facilitates prolonged utilization in adults based on extracorporeal membrane oxygenation (ECMO), an essential life support technique for individuals experiencing cardiac and pulmonary complications.

In November 2022, LivaNova PLC announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. The approval indicates that the LifeSPARC system complies with the standards established by the FDA, allowing for its utilization in the U.S. market.

In July 2022, Inspira Technologies OXY B.H.N Ltd., a leader in life support technology, launched the "Liby" System. This sophisticated life support system is engineered to manage patients experiencing critical heart and lung failure.

In July 2021, Xenios AG, a subsidiary of Fresenius Medical Care, obtained approval from the National Medical Products Administration (NMPA) in China for the utilization of its Xenios Console and patient kits in ECMO therapy. The approval follows the successful registration of two patient kits in China.

Extracorporeal Membrane Oxygenation Machine Market, By Category

  • Component:
  • Pumps
  • Oxygenator
  • Controllers
  • Cannula
  • Accessories
  • Services:
  • Veno-Venous
  • Veno-Arterial
  • Arterio-Venous
  • Patient Type:
  • Neonates
  • Pediatric
  • Adult
  • Application:
  • Respiratory
  • Neonates
  • Pediatric
  • Adult
  • Cardiac
  • Neonates
  • Pediatric
  • Adult
  • ECPR
  • Neonates
  • Pediatric
  • Adult
  • Region:
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Extracorporeal Membrane Oxygenation Machine Market Geographical Analysis (CAGR %)
  • 3.6 Global Extracorporeal Membrane Oxygenation Machine Market, By Patient Type (USD Million)
  • 3.7 Global Extracorporeal Membrane Oxygenation Machine Market, By Application (USD Million)
  • 3.8 Global Extracorporeal Membrane Oxygenation Machine Market, By Modality (USD Million)
  • 3.9 Global Extracorporeal Membrane Oxygenation Machine Market, By Component (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET OUTLOOK

  • 4.1 Global Extracorporeal Membrane Oxygenation Machine Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY COMPONENT

  • 5.1 Overview
  • 5.2 Pumps
  • 5.3 Cannula
  • 5.4 Oxygenator
  • 5.5 Accessories
  • 5.6 Controller

6 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY SERVICES

  • 6.1 Overview
  • 6.2 Veno- Arterial
  • 6.3 Veno-Venous
  • 6.4 Arterio-Venous

7 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY PATIENT TYPE

  • 7.1 Overview
  • 7.2 Adult
  • 7.3 Pediatric
  • 7.4 Neonates

8 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Respiratory
    • 8.2.1 Neonates
    • 8.2.2 Pediatric
    • 8.2.3 Adult
  • 8.3 ECPR
    • 8.3.1 Neonates
    • 8.3.2 Pediatric
    • 8.3.3 Adult
  • 8.4 Cardiac
    • 8.4.1 Neonates
    • 8.4.2 Pediatric
    • 8.4.3 Adult

9 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Medtronic
    • 11.1.1 Company Overview
    • 11.1.2 Company Insights
    • 11.1.3 Product Benchmarking
    • 11.1.4 Key Developments
    • 11.1.5 Winning Imperatives
    • 11.1.6 Current Focus & Strategies
    • 11.1.7 Threat from Competition
    • 11.1.8 SWOT Analysis
  • 11.2 Fresenius Medical Care A.G. & Co. KGAA
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Developments
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.3 Maquet Holding
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Developments
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Getinge Group
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Developments
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Microport
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Developments
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Origin Biomedical
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Developments
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Terumo Cardiovascular Systems Corporation
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Developments
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Livanova plc
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Developments
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Nipro Corporation
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Developments
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 Euro sets S.R.L.
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Developments
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET INTELLIGENCE

  • 12.1 About Verified Market Intelligence
  • 12.2 Dynamic Data Visualization